Synthetic Biologics stock plunges to 52-week low at $1.02

Synthetic Biologics Inc (NYSE: TOVX), a clinical-stage company focused on developing therapeutics for the gut microbiome, has seen its stock tumble to a 52-week low, touching down at $1.02. With a current market capitalization of just $3 million, InvestingPro analysis suggests the stock is currently undervalued relative to its Fair Value. This latest price point marks a significant downturn for the company, which has experienced a staggering 1-year change with a decline of -90.76%. While the company holds more cash than debt on its balance sheet and maintains a healthy current ratio of 2.15, InvestingPro data reveals the company is quickly burning through cash. Investors have been closely monitoring Synthetic Biologics as it navigates through a challenging period, with market sentiment reflecting the hurdles the company faces in advancing its pipeline and securing a stable financial position amidst a competitive biotech landscape. For deeper insights, including 8 additional ProTips and comprehensive financial analysis, check out the full research report available on InvestingPro.

In other recent news, Theriva Biologics announced that its VIRAGE Phase 2b clinical trial for metastatic pancreatic ductal adenocarcinoma has shown positive safety data for its candidate VCN-01. The Independent (LON:IOG) Data Monitoring Committee reviewed safety data from 101 patients and found VCN-01 to be well tolerated in combination with standard chemotherapy. The adverse events reported were consistent with previous trials and were found to be transient and reversible, with fewer and less severe events following the second dose. The VIRAGE trial, which completed patient enrollment in September 2024, is assessing the efficacy of VCN-01 alongside chemotherapy agents gemcitabine and nab-paclitaxel. Theriva Biologics anticipates topline clinical outcomes from the trial in the second quarter of 2025. These developments are expected to inform the design of a potential Phase 3 registrational trial. The trial's primary endpoints include overall survival and safety/tolerability, with additional assessments on progression-free survival and objective response rate. CEO Steven A. Shallcross expressed confidence in the repeated dosing of VCN-01 for metastatic PDAC patients.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.